Atlas Trials

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Clinical trial NCT04362813 · COMPLETED

Trial details

NCT number
NCT04362813
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Start date
2020-04-30
Primary completion
2020-09-16
Enrollment
454

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.